Enhertu, a breast cancer drug that targets the HER2 protein, has been shown to reduce the risk of disease progression or death in people with metastatic disease whose tumors have very low levels of the protein, according to a new study published in The New England Journal of Medicine. Sylvia Adams, MD, director of the Breast Cancer Center at NYU Langone Health’s Perlmutter Cancer Center, enrolled several patients in the study.
“It’s a practice-changing study,” says Dr. Adams, also a professor in the Department of Medicine at NYU Grossman School of Medicine. “It addresses a major unmet need for patients who have metastatic breast cancer,” Dr. Adams tells the Associated Press.
Read more from the Associated Press.